Capital World Investors Grows Stock Holdings in Amgen Inc. $AMGN

Capital World Investors increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 22.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,097,711 shares of the medical research company’s stock after buying an additional 4,302,237 shares during the period. Amgen comprises 1.0% of Capital World Investors’ portfolio, making the stock its 19th largest holding. Capital World Investors’ holdings in Amgen were worth $7,560,249,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen during the fourth quarter worth about $26,000. Manning & Napier Advisors LLC boosted its holdings in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC purchased a new stake in Amgen during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Amgen Stock Performance

Shares of AMGN opened at $349.58 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market cap of $188.67 billion, a P/E ratio of 24.33, a PEG ratio of 3.51 and a beta of 0.42. The company has a 50-day moving average of $341.35 and a two-hundred day moving average of $345.47. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on AMGN. Royal Bank Of Canada boosted their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Mizuho boosted their price objective on shares of Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Piper Sandler cut their target price on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Barclays assumed coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Finally, Truist Financial lifted their target price on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $353.81.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.